Management of Statin-Associated Muscle Symptoms

Evaluation and Discontinuation

• When statin-associated muscle symptoms develop, temporarily discontinue the statin, evaluate for underlying causes, and rechallenge with the same or different statin at a lower dose after symptoms resolve to establish causality and maintain cardiovascular risk reduction benefits, as recommended by the American College of Cardiology 1
• For patients with severe symptoms, promptly discontinue statin therapy, evaluate for rhabdomyolysis by checking creatine kinase levels, serum creatinine, and urinalysis for myoglobinuria, and monitor renal function, as recommended by the American College of Cardiology 1
• Discontinue statin therapy if signs of hepatotoxicity arise, such as unusual fatigue, loss of appetite, abdominal pain, dark urine, or yellowing of skin/sclera, as recommended by the American College of Cardiology 1

Rechallenge and Risk Assessment

• After symptom resolution, rechallenge with the original statin at the same or lower dose, or a lower dose of a different statin (consider less lipophilic statins), if no contraindication exists, as recommended by the American College of Cardiology 1
• Evaluate patients for other conditions that may increase the risk of statin-associated muscle symptoms, including hypothyroidism, reduced renal or hepatic function, rheumatologic disorders, vitamin D deficiency, and primary muscle diseases, as recommended by the American College of Cardiology 1
• Consider exercising particular caution with elderly patients (>80 years), small-framed or frail individuals, patients with multisystem disease, those on multiple medications, and Asian patients (particularly with rosuvastatin) when selecting a statin, as suggested by the European Heart Journal and the American College of Cardiology 2, 3, 4

Patient Education and Monitoring

• Instruct patients to report muscle discomfort, weakness, or brown urine immediately, and explain that most muscle symptoms (>90%) reported by patients on statins are not actually due to the statin, as recommended by the American College of Cardiology 3, 5
• Emphasize the importance of cardiovascular risk reduction and the small risk of true statin-related muscle symptoms compared to benefits, as recommended by the American College of Cardiology 3
• Establish baseline values for lipid panels, liver function tests, and CK measurement before starting statin therapy, as recommended by the American College of Cardiology 3, 6
• Evaluate muscle symptoms at 6-12 weeks after starting therapy and monitor symptoms at each follow-up visit, with CK measurement when muscle soreness, tenderness, or pain occurs, as suggested by the American College of Cardiology 3

Alternative Therapies

• Consider non-statin alternatives, such as ezetimibe 10 mg daily (reduces LDL-C by 15-20%), bile acid sequestrants, or PCSK9 inhibitors for high-risk patients, as reported by 7
• The following table summarizes the recommended doses and LDL-C reductions for alternative medications:

• Consider combination therapy with bempedoic acid or a PCSK9 inhibitor for statin-intolerant patients not achieving goals on ezetimibe alone, as recommended by the European Society of Cardiology and the European Heart Journal 8, 9

Special Populations

• Women with homozygous familial hypercholesterolemia (HoFH) and established cardiovascular disease may consider continuing statins during pregnancy, particularly after the first trimester, while all other pregnant women should discontinue statins when pregnancy is recognized or ideally 3 months before planned conception, as suggested by the American Heart Association and other guideline societies 10
• Bile acid sequestrants can be used during pregnancy and lactation, as stated by the European Society of Cardiology and other guideline societies 10

Medication Interactions

• Avoid combining statins with medications that increase risk of muscle symptoms, including fibrates (especially gemfibrozil), cyclosporine, macrolide antibiotics (erythromycin, clarithromycin), azole antifungals (itraconazole, ketoconazole), HIV protease inhibitors, amiodarone, and large quantities of grapefruit juice, as warned by the American College of Cardiology and the American Heart Association 3, 11

Adherence and Outcomes

• Up to 50% of primary prevention patients stop statin therapy within 6 months, and non-adherence is associated with increased cardiovascular events, stroke risk, and mortality, according to the European Society of Cardiology 2
• True correlation between muscle pain and statin use is uncommon, approximately 1%, as reported by the European Heart Journal 2
• Schedule follow-up appointments to monitor symptoms and reinforce adherence, as recommended by the European Society of Cardiology 2